Idiopathic Thrombocytopenic Purpura
3 competing products in clinical development for Idiopathic Thrombocytopenic Purpura.
Pipeline by Phase
Phase 11
Phase 21
Phase 31
All Products (3)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Blinded (placebo) + Open Label (Avatrombopag tablets) + Blinded (Avatrombopoag tablets) | Eisai | Phase 2 | Completed | 35 |
| Eltrombopag + Avatrombopag + Standard of care | Eisai | Phase 3 | Terminated | 32 |
| 10-mg dose of E5501 2G tablet + 10-mg dose of E5501 cyclodextrin oral solution + 10-mg dose of E5501-P21% powder + 10-mg dose of E5501 lipid-based oral | Eisai | Phase 1 | Completed | 29 |